Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Alexander Chi83 enrolled

Overview

This study will explore the best dose of radiation to be used when treating stage I-III non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or hypo-fractionated radiotherapy (HypoFrx-RT) that is delivered in combination with an immune checkpoint inhibitor. Treatments with SBRT or HypoFrx-RT for locally confined NSCLC show positive response which may be further augmented when they are combined with an immune checkpoint inhibitor. Currently, it is not understood what radiation dose is most suitable for such combined treatments and their clinical efficacy in the treatment of early stage (ES) NSCLC. Therefore, this study can help researchers gain insight into what a safe and effective SBRT or HypoFrx-RT dose will be when such radiotherapeutic approaches are combined with concurrent and adjuvant administration of an immune checkpoint inhibitor in the treatment of ES NSCLC.

Patients will be assigned to Cohort A or Cohort B based on tumor stage (AJCC 8th Ed.). Cohort A: cT1-T3, N0, M0 (selected cT1, No, M0) Cohort B: cT4, N0, M0; cT1-4, N1-3, M0 Phase I: This portion of the study will utilize a standard 3 + 3 phase I design with three patients enrolled per radiation dose level in each cohort. Enrollment in the two cohorts is independent from one another. In both cohorts, an anti-PD-(L)1 immune checkpoint inhibitor will be given concurrently and adjuvantly with radiotherapy for approximately 1 year. The radiation dose escalation for each cohort is listed below: Cohort A (SBRT): (Optional): 8 Gy x 5 daily fractions Level 1: 9 Gy x 5 daily fractions Level 2: 10 Gy x 5 daily fractions Level 3: 11 Gy x 5 daily fractions Cohort B (HypoFrx-RT): (Optional): 3 Gy x 15 daily fractions Level 1: 3.5 Gy x 15 daily fractions Level 2: 4 Gy x 15 daily fractions DLTs will be based on events occurring during the course of radiotherapy. Concurrent administration of an immune checkpoint inhibitor is defined as: An anti-PD-(L)1 immune checkpoint inhibitor administered with standard dosing (Durvalumab: 1500 mg every 4 weeks) given within 5 days prior to the beginning of radiotherapy. Adjuvant administration of an immune checkpoint inhibitor is defined as: An anti-PD-(L)1 immune checkpoint inhibitor administered with standard dosing (Durvalumab: 1500 mg every 4 weeks) for approximately 1 year or until progression or other discontinuation criteria are met. Phase II: Once a maximum tolerated dose (MTD) is defined in each cohort, this dose will be used as the only radiation dose in each corresponding cohort in the phase II portion of this study. Dosing regimen of the immune checkpoint inhibitor will remain the same as that used in the phase I portion of this study. For this protocol, patients will be followed up to 2 years after the last dose of immune checkpoint inhibitor is administered.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Key Inclusion Criteria 1. Informed Consent 2. Stage I-III NSCLC per AJCC 8th. ed. 3. Tumor PD-L1 expression ≥1% preferred 4. Tumor sample submission 5. Tumor staging prior to registration 6. Age ≥ 18 years 7. WHO/ECOG PS of 0, 1, or 2 8. Life expectancy ≥12 weeks 9. Adequate organ or bone marrow function 10. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Exclusion Criteria: Key Exclusion Criteria 1. Mixed small cell and non-small cell lung cancer histology 2. Definitive clinical or radiologic evidence of metastatic disease 3. Patients who received systemic therapy for the current cancer prior to enrollment 4. Thoracic radiotherapy within 5 years with exceptions 5. Major surgery within 28 days prior to enrollment with exception 6. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody 7. History of another primary malignancy with exceptions 8. History of idiopathic pulmonary fibrosis, any pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on chest PET/CT or CT scan 9. Active or prior documented autoimmune disease with exceptions 10. History of primary immunodeficiency 11. History of allogenic organ or tissue transplantation

Outcomes

Primary Outcomes

Maximum tolerated dose (MTD)

MTD in cohort A and cohort B, respectively.

Time frame: 2 years

The incidence of any adverse events that is >= grade 3

Adverse events will be graded according to CTCAE v.5.0

Time frame: 2 years

Progression-free survival (PFS)

PFS is defined as free from any disease progression or death after combined treatment for NSCLC.

Time frame: 2 years

Secondary Outcomes

Local control

To report the local control rate along with the rate of regional control and distant metastasis after combined treatment for NSCLC.

Time frame: 2 years

Overall survival (OS)

To report OS after combined treatment

Time frame: 2 years

Quality of Life (QoL)

To determine the QoL pertaining to any cancer patients before and after treatment using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) scales.

Time frame: 2 years

Quality of Life (QoL), Lung cancer specific

To determine the QoL before and after treatment using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire that is specific to lung cancer patients, the Lung Cancer 29(LC 29) scoring scales.

Time frame: 2 years

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts